Exercise Training and Metabolic Syndrome

Effects of Aerobic Interval Training on Clinical Biomarkers and Quality of Life in Metabolic Syndrome

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03036332

Enrollment

Registered

2017-01-30

Start date

2015-06-01

Completion date

2016-12-10

Last updated

2017-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome

Keywords

aerobic interval training, biomarkers

Brief summary

The present study aimed to determine the effects of 16 weeks of aerobic interval training on quality of life and a set of clinical biomarkers.

Detailed description

Besides the traditional metabolic syndrome risk factors (dyslipidemia, raised blood pressure, central obesity and dysglycemia) subclinical disorders related to chronic inflammation and cell damage have been reported on metabolic syndrome. Therefore, regarding the systemic feature of metabolic syndrome, we investigated an new approach of aerobic interval training on several clinical biomarkers widely used. Such training used differs from current aerobic protocols in order to attenuate metabolic and musculoskeletal overload on untrained and unhealthy subjects.

Interventions

BEHAVIORALAerobic interval training

Carried out 3 times per week for 16 weeks

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

35 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Having metabolic syndrome according to international diabetes foundations definition (IDF). * Age between 35 - 60 years and untrained subjects.

Exclusion criteria

* Musculotendinous or osteoarticular injuries in the lower limbs and/or spine * Chronic pulmonary diseases * Neurological disorders * Kidney failure * High-risk cardiovascular diseases (Unstable angina pectoris, Uncompensated heart failure, complex ventricular arrhythmias or myocardial infarction during the last month).

Design outcomes

Primary

Measure	Time frame	Description
Pro-inflammatory marker	16 weeks	Serum levels of C-reactive protein

Secondary

Measure	Time frame	Description
Quality of life	16 weeks	The Medical Outcomes Study-Short Form 36 (SF-36)
A set of clinical biomarkers	16 weeks	Serum levels lof Homocysteine; Creatinine, Creatine kinase (ck); creatine kinase MB (ck-mb); Troponin t; aspartate aminotransferase; alanine aminotransferase; and complete blood count.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026